Results 101 to 110 of about 216,413 (307)

Exploring the equity of GP practice prescribing rates for selected coronary heart disease drugs: a multiple regression analysis with proxies of healthcare need [PDF]

, 2005
Background There is a small, but growing body of literature highlighting inequities in GP practice prescribing rates for many drug therapies. The aim of this paper is to further explore the equity of prescribing for five major CHD drug groups and to ...
A Gibson, A Majeed, A Majeed, A Majeed, A Williams, AM Tod, Antony S St Leger, B Hope, BH Foundation, C Baxter, C Packham, C Packham, D Health, D Health, D Health, D Health, DC Lloyd, DC Lloyd, EUROASPIREII Group., FA Majeed, FA Majeed, FDA Reid, G Davey-Smith, G Davey-Smith, GC Fonarow, H Cooper, H Tunstall-Pedoe, J Bedson, J Hippisley-Cox, J Tudor Hart, JHS Unit, JI Mann, JY Nazroo, K Gardner, M Frischer, M Goddard, M Pringle, M Whitehead, M Whitehead, MC MacLeod, MG Hunink, MG Patel, N Bradshaw, N Chaturvedi, N Danchin, N Rice, NC Campbell, NHS Centre for Reviews and Dissemination, ON Statistics, P Jousilahti, P Primatesta, P Suadicani, P Townsend, Paul R Ward, Peter R Noyce, PG Steg, PH Whincup, PR Ward, PR Ward, PR Ward, PS Unit, PS Unit, R Bhopal, R Bhopal, RM Haynes, S Hopper, S Kerrison, S Langham, S Peckham, SM Bogle, SR Chapman, SS Gottlieb, T Crayford, T Morton-Jones, T Walley, TJ Wang, V Salomaa, WH Organisation.   +77 more
core   +4 more sources

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Unpacking and understanding the impact of proprotein convertase subtilisin/kexin type 9 inhibitors on apolipoprotein B metabolism [PDF]

, 2017
No abstract ...
Packard, Chris J.
core   +1 more source

Nonadherence and uncontrolled arterial hypertension in Croatia—Insights from the May Measurement Month 2023 campaign and Hunting the silent killer programme

British Journal of Clinical Pharmacology, EarlyView.
Aims To determine the prevalence of non‐adherence to antihypertensive medicines and to identify demographic and behavioral factors associated with non‐adherence in subjects enrolled in the May Measurement Month (MMM) 2023, as part of the permanent public health action Hunting the silent killer.
Valerija Bralić Lang, Ana Soldo, Olgica Velkovski Škopić, Sunčana Vlah Tomičević, Tin Šaban, Andrej Belančić, Ana Jelaković, Josipa Josipović, Mihaela Marinović Glavić, Ivan Pećin, Luka Prgomet, Tajana Željković Vrkić, Bojan Jelaković   +12 more
wiley   +1 more source

Redemptive benefit of atorvastatin in the risk factors of coronary artery disease [PDF]

, 2011
Cardiovascular disease, in particular coronary artery disease (CAD), is the principal cause of mortality in developed countries. The classical acute phase protein, C-reactive protein (CRP) is an exquisitely sensitive systemic marker of disease ...
Jayaraman Gowri , Arumugam Vijaya Anand , Shanmugam Achiraman , Govindha Raj Archunan , Subramaniyam Kalavathy , Palanisamy Sampath Kumar , Kalaiyarasan Vijaya Kumar Int J Cur Biomed Phar Res.
core  

Statins and non-alcoholic fatty liver disease [PDF]

, 2019
Dear Editor, In April 9 issue, van den Berg et al1 report interesting results on the indication for lipid‐lowering treatment in a large cohort with suspected non‐alcoholic fatty liver disease (NAFLD) within the population‐based Lifelines Cohort Study.
Angelico, F, Baratta, F, Del Ben, M, Pastori, D   +3 more
core   +1 more source

Fostering medication review competence of pharmacy students: An assessment by students and their preceptors after advanced‐level practical internship

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this study was to introduce a new assessment method for pharmacy students' real‐life competence in reviewing medications after obligatory advanced‐level practical internship in Finland. Methods The new medication review (MR) competence assessment method consisted of (1) a self‐assessment by pharmacy students and (2) a performance ...
Katja Leiman, Aleksi Westerholm, Tero Vahlberg, Noora Lias, Tanja Lindholm, Marja Airaksinen   +5 more
wiley   +1 more source

Statins, but not proprotein convertase subtilisin‐kexin type 9 inhibitors, lower chemerin in hypercholesterolemia via low‐density lipoprotein receptor upregulation

MedComm
Hypercholesterolemia is characterized by elevated low‐density lipoprotein (LDL)‐cholesterol levels and an increased risk of cardiovascular disease. The adipokine chemerin is an additional risk factor.
Lunbo Tan, Na Wang, Annet M. H. Galema‐Boers, Leonie vanVark‐van der Zee, Jeanine Roeters vanLennep, Monique T. Mulder, Xifeng Lu, A. H. Jan Danser, Koen Verdonk   +8 more
doaj   +1 more source

Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. [PDF]

, 2006
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is a critical enzyme in the mevalonate pathway that regulates the biosynthesis of cholesterol as well as isoprenoids that mediate the membrane association of certain GTPases.
Dunn, Shannon E, Goldstein, Matthew J, Prod'homme, Thomas, Steinman, Lawrence, Weber, Martin S, Youssef, Sawsan, Zamvil, Scott S   +6 more
core   +1 more source

The pharmacology of statins

Pharmacological Research, 2014
Statins, inhibitors of the hydroxymethylglutaryl-CoA (HMG-CoA) reductase enzyme, are molecules of fungal origin. By inhibiting a key step in the sterol biosynthetic pathway statins are powerful cholesterol lowering medications and have provided outstanding contributions to the prevention of cardiovascular disease. Their detection in mycetes traces back
openaire   +2 more sources